Overview

An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051

Status:
Active, not recruiting

Trial end date:
2024-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this extension study is to evaluate the safety, tolerability, and pharmacokinetics of repeat administrations of SRP-5051 in patients with Duchenne muscular dystrophy (DMD) who participated in studies of SRP-5051.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sarepta Therapeutics
Sarepta Therapeutics, Inc.